Literature DB >> 12297571

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study.

Peter P Zandi1, James C Anthony, Kathleen M Hayden, Kala Mehta, Lawrence Mayer, John C S Breitner.   

Abstract

BACKGROUND: Previous analyses from the Cache County (UT) Study showed inverse associations between the prevalence of AD and the use of nonsteroidal anti-inflammatory drugs (NSAID), aspirin compounds, or histamine H(2) receptor antagonists (H(2)RA). The authors re-examined these associations using data on incident AD.
METHODS: In 1995 to 1996, elderly (aged 65+) county residents were assessed for dementia, with current and former use of NSAID, aspirin, and H(2)RA as well as three other "control" medication classes also noted. Three years later, interval medication histories were obtained and 104 participants with incident AD were identified among 3,227 living participants. Discrete time survival analyses estimated the risk of incident AD in relation to medication use.
RESULTS: AD incidence was marginally reduced in those reporting NSAID use at any time. Increased duration of use was associated with greater risk reduction, and the estimated hazard ratio was 0.45 with >/=2 years of exposure. Users of NSAID at baseline showed little reduction in AD incidence, regardless of use thereafter. By contrast, former NSAID users showed substantially reduced incidence (estimated hazard ratio = 0.42), with a trend toward greatest risk reduction among those with extended exposure. Similar patterns appeared with aspirin but not with any other medicines examined.
CONCLUSIONS: Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. More recent exposure seems to offer little protection. Recently initiated randomized trials of NSAID for primary prevention of AD are therefore unlikely to show effects with treatment until participants have been followed for several years.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297571     DOI: 10.1212/wnl.59.6.880

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  102 in total

Review 1.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

3.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

Review 4.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

5.  Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.

Authors:  Michelle M Mielke; Jeannie-Marie Leoutsakos; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; JoAnn T Tschanz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 6.  Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.

Authors:  Elizabeth E Spangenberg; Kim N Green
Journal:  Brain Behav Immun       Date:  2016-07-06       Impact factor: 7.217

Review 7.  Medications and diet: protective factors for AD?

Authors:  Claudia H Kawas
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jul-Sep       Impact factor: 2.703

8.  Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.

Authors:  Paul Lochhead; Kaitlin Hagan; Amit D Joshi; Hamed Khalili; Long H Nguyen; Francine Grodstein; Andrew T Chan
Journal:  Gastroenterology       Date:  2017-07-18       Impact factor: 22.682

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 10.  Inflammatory mechanisms in neurodegeneration.

Authors:  Michael R Nichols; Marie-Kim St-Pierre; Ann-Christin Wendeln; Nyasha J Makoni; Lisa K Gouwens; Evan C Garrad; Mona Sohrabi; Jonas J Neher; Marie-Eve Tremblay; Colin K Combs
Journal:  J Neurochem       Date:  2019-03-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.